Molecular epidemiology of lung cancer in female passive smokers

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 23, Issue 1, 2005, Pages 75-97

  Yang, Mihi ^a   Pyo, Myung Yun ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Biological monitoring; Environmental tobacco smoking; Exposure biomarker; Female; Lung cancer; Molecular epidemiology; Non smoker

Indexed keywords

DNA; ENZYMES; EPIDEMIOLOGY; GENES; METABOLISM; PULMONARY DISEASES; SOCIAL ASPECTS;

ENVIRONMENTAL TOBACCO SMOKING (ETS); ETIOLOGY; LUNG CANCER; MOLECULAR EPIDEMIOLOGY;

TUMORS;

1 HYDROXYPYRENE; 1 NAPHTHOL; 2 NAPHTHOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 BIPHENYLAMINE; 8 HYDROXYDEOXYGUANOSINE; 8 HYDROXYGUANINE; COTININE; CYTOCHROME P450 1A1; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUTATHIONE TRANSFERASE; HEMOGLOBIN; NICOTINE; NITROSAMINE; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; ANIMAL MODEL; BIOLOGICAL MONITORING; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONTROLLED STUDY; DNA ADDUCT; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PASSIVE SMOKING; REVIEW; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; TOBACCO; URINARY EXCRETION;

DISEASE SUSCEPTIBILITY; ENVIRONMENTAL MONITORING; EPIDEMIOLOGY, MOLECULAR; FEMALE; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; SEX FACTORS; TOBACCO SMOKE POLLUTION;

ANIMALIA; NICOTIANA TABACUM;

EID: 17144418534     PISSN: 10590501     EISSN: None     Source Type: Journal    
DOI: 10.1081/GNC-200052205     Document Type: Review

References (103)

1. Jee SH, Ohrr H, Kim IS. Effects of husbands' smoking on the incidence of lung cancer in Korean women. Int J Epidemiol 1999;28(5):824-828.
2. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Cancer Biol 2004;14(6):473-486.
3. Lodovici M, Akpan V, Evangelisti C, Dolara P. Sidestream tobacco smoke as the main predictor of exposure to polycyclic aromatic hydrocarbons. J Appl Toxicol 2004;24(4):277-281.
4. Bilello KS, Murin S, Matthay RA. Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med 2002;23:1-25.
5. Schulte PA, Perera FP. Molecular epidemiology. Academic press, 1993.
6. Haugen A. Women who smoke: are women more susceptible to tobacco-induced lung cancer? Carcinogenesis 2002;23(2):227-229.
7. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993;138(5):281-293.
8. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996;88(3-4):183-192.
9. McDuffie HH, Klaassen DJ, Dosman JA. Female-male differences in patients with primary lung cancer. Cancer 1987;59:1825-1830.
10. National cancer center, Korea, http://www.ncc.re.kr/files/statistics/ Cancer%20 Statistics%20in%20KOREA.doc
11. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE, Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988;48:7279-7284.
12. Blot WJ, McLaughlin JK. Are women more susceptible to lung cancer? J Natl Cancer Inst 2004;96(11):812-813.
13. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95(6):470-478.
14. Patel JD, Bach PB, Kris MG. Lung Cancer in US Women: A Contemporary Epidemic. JAMA 2004;291(14):1763-1768.
15. Siegfried JM. Women and lung cancer: does oestrogen play a role? Lancet Oncol 2001;2(8):506-513.
16. Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus AM, Petruzzelli S, Giuntini C, Bartsch H. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 1992;52:6248-6253.
17. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Mines RN. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990;82:1333-1339.
18. Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999;59(14):3317-3320.
19. Gasperino J, Rom WN. Gender and lung cancer. Clin Lung Cancer 2004;5(6): 353-359.
20. Stabile LP, Siegfried JM. Sex and gender differences in lung cancer. J Gend Specif Med 2003;6:37-48.
21. Berge G, Mollerup S, OVrebo S, Hewer A, Phillips DH, Eilertsen E, Haugen A. Role of estrogen receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung Cancer 2004;45(3):289-297.
22. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women?. Int J Epidemiol 2003;32:263-271.
23. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004;10(1 Pt 1):113-123.
24. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000;30(3):153-160.
25. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stucker I, Sugimura H, Taioli E. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 2003;14(4):339-346.
26. Landi S Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000;463(3):247-283.
27. Fields WR, Morrow CS, Doss AJ, Sundberg K, Jernstrom B, Townsend AJ. Overexpression of stably transfected human glutathione s-transferase P1-1 protects against DNA damage by benzo[]pyrene diol-epoxide in human T47D cells. Mol Pharmacol 1998;54:298-304.
28. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione s-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998;19:275-280.
29. Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, Ogreid D, Ulvik A, Vu P, Haugen A. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 1997;18:1285-1289.
30. Butkiewicz D, Grzybowska E, Phillips DH, Hemminki K, Chorazy M. Polymorphisms of the GSTP1 and GSTM1 genes and PAH-DNA adducts in human mononuclear white blood cells. Environ Mol Mutagen 2000;35:99-105.
31. Miller DP, Neuberg D, de Vivo I, Wain JC, Lynch TJ, Su L, Christiani DC. Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms. Epidemiology 2003;14:545-551.
32. Yang M, Choi Y, Kim I, Park S, Yoo K, Lee J. Genetic etiology for Korean lung cancer. Proceeding of the 55th annual meeting of the Korean society for Preventive Medicine. 2003;323.
33. Coles, BF, Yang M, Lang NP, Kaldubar FF. Expression of GSTP1 alleles in human lung and activity of the native protein variants towards 4-vinylpyridine, arachidonate hydroperoxide, linoleate hydroperoxide, 1-chloro-2,4-dinitrobenzene and (+)-antibenzo[a]pyrene-7,8-diol,9,10 epoxide. Cancer Letters 2000;156:167-175.
34. NIEHS (National Institue, Environmental genome project. http://www.niehs. nih.gov/envgenom/egp6.htm.
35. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274:430-432.
36. Smith LE, Denissenko MF, Bennet WP, Li H, Amin S, Tang M, Pfeifer GP. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-811.
37. Kure EH, Ryberg D, Hewer A, Phillips DH, Skaug V, Bsera R, Haugen A. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996;17:2201-2205.
38. Guinee DG Jr, Travis WD, Trivers GE, De Benedetti VM, Cawley H, Welsh JA, Bennett WP, Jett J, Colby TV, Tazelaar H. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 antibodies and C-erbB-2 expression. Carcinogenesis 1995;16:993-1002.
39. Pulling LC, Divine KK, Klinge DM, Gilliland FD, Kang T, Schwartz AG, Bocklage TJ, Belinsky SA. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res. 2003;63(16):4842-4848.
40. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91(23):2032-2038.
41. Wei Q, Cheng L, Amos CI, Wang L-E, Guo Z, Hong WK, Spitz MR. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764-1772.
42. University of Manitoba, http://quitsmoking.about.com/gi/dynamic/offsite. htm? site=http%3A%2F%2Fwww.umanitoba.ca%2Ffaculties%2Fdentistry%2Foral_biology% 2Fresearch%2Fjournal%2Fonline%2Fpassive_2.html
43. Action on smoking and health, http://www.ash.org.uk/html/passive/html/ passive. html#_Toc73180386
44. Hackshaw AK. Lung cancer and passive smoking. Stat Methods Med Res 1998;7(2):119-36
45. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. Br Med J 1997;315:980-988.
46. Brennan P, Buffler PA, Reynolds P, Wu AH, Wichmann HE, Agudo A, Pershagen G, Jockei KH, Benhamou S, Greenberg RS, Merletti F, Winck C, Fontham ET, Kreuzer M, Darby SC, Forastiere F, Simonato L, Boffetta P. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer 2004;109(1):125-131.
47. Boffetta P, Agudo A, Ahrens W, Benhamou E, Benhamou S, Darby SC, Ferro G, Fortes C, Gonzalez CA, Jockel KH, Krauss M, Kreienbrock L, Kreuzer M, Mendes A, Merletti F, Nyberg F, Pershagen G, Pohlabeln H, Riboli E, Schmid G, Simonato L, Tredaniel J, Whitley E, Wichmann HE, Saracci R. Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. J Natl Cancer Inst 1998;90(19):1440-1450.
48. Lee CH, Ko YC, Goggins W, Huang JJ, Huang MS, Kao EL, Wang HZ. Lifetime environmental exposure to tobacco smoke and primary lung cancer of non-smoking Taiwanese women. Int J Epidemiol 2000;29(2):224-231.
49. Cheng YW, Lee H. Environmental Exposure and Lung Cancer Among Nonsmokers: An Example of Taiwanese Female Lung Cancer. Journal of Environmental Science and Health, Part C - Environmental Carcinogenesis & Ecotoxicology Reviews 2003;C21:1-28.
50. Wang TJ, Zhou BS. Meta-analysis of the potential relationship between exposure to environmental tobacco smoke and lung cancer in nonsmoking Chinese women. Lung Cancer 1997;16(2-3):145-150.
51. Mumford JL, Li X, Hu F, Lu XB, Chuang JC. Human exposure and dosimetry of polycyclic aromatic hydrocarbons in urine from Xuan Wei, China with high lung cancer mortality associated with exposure to unvented coal smoke. Carcinogenesis 1995;16(12):3031-3036.
52. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N, Rothman N. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004;25(11):2177-2181.
53. de Andrade M, Ebbert JO, Wampner JA, Miller DL, Marks RS, Croghan GA, Jatoi A, Finke EE, Sellers TA, Yang P. Environmental tobacco smoke exposure in women with lung cancer. Lung Cancer 2004;43(2):127-134.
54. Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean men and women. Cancer Causes Control 2004;15(4):341-348.
55. Sexton K, Adgate JL, Church TR, Hecht SS, Ramachandran G, Greaves IA, Fredrickson AL, Ryan AD, Carmella SG, Geisser MS. Children's exposure to environmental tobacco smoke: using diverse exposure metrics to document ethnic/racial differences. Environ Health Perspect 2004;112(3):392-327.
56. Jongeneelen FJ, Anzion RB, Leijdekkers CM, Bos RP, Henderson PT. 1-hydroxypyrene in human urine after exposure to coal tar and a coal tar derived product. Int Arch Occup Environ Health 1985;57(1):47-55.
57. Hara K, Hanaoka T, Yamano Y, Itani T. Urinary 1-hydroxypyrene levels of garbage collectors with low-level exposure to polycyclic aromatic hydrocarbons. Sci Total Environ 1997;199(1-2):159-164.
58. Carmella SG, Le KA, Hecht SS. Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiol Biomarkers Prev 2004;13(7):1261-1264.
59. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23(6):907-922.
60. Yang M, Kim S, Lee E, Cheong H, Chang S, Kang D, Choi Y, Lee S, Jang J. Sources of Polycyclic Aromatic Hydrocarbon Exposure in Non Occupationally Exposed Koreans. Environmental and Molecular mutagenesis 2003;42:250-257.
61. Yang M, Jang JY, Kim S, Lee SM, Chang SS, Cheong HK, Lee E, Kang D, Kim H, Kawamoto T, Shin HD. Genetic effects on urinary 1-hydroxypyrene levels in a Korean population. Carcinogenesis 2003;24(6):1085-1089.
62. Nerurkar PV, Okinaka L, Aoki C, Seifried A, Lum-Jones A, Wilkens LR, Le Marchand L.CYP1A1, GSTM1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol Biomarkers Prev 2000;9(10):1119-1122.
63. Lee CY, Lee JY, Kang JW, Kim H. Effects of genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 on the urinary levels of 1-hydroxypyrene and 2-naphthol in aircraft maintenance workers. Toxicol Lett 2001;123(2-3):115-124.
64. Alexandrie AK, Warholm M, Carstensen U, Axmon A, Hagmar L, Levin JO, Ostman C, Rannug A. CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure. Carcinogenesis 2000;21(4):669-676.
65. Apostoli P, Neri G, Lucas D, Manno M, Berthou F. Influence of genetic polymorphisms of CYP1A1 and GSTM1 on the urinary levels of 1-hydroxypyrene. Toxicol Lett 2003;144(1):27-34.
66. Wu MT, Pan CH, Chen CY, Chen CJ, Huang LH, Tsai LY, Huang CT, Ho CK. Lack of modulating influence of GSTM1 and GSTT1 polymorphisms on urinary biomonitoring markers in coke-oven workers. Am J Ind Med 2004;46(2):112-119.
67. Murphy SE, Link CA, Jensen J, Le C, Puumala SS, Hecht SS, Carmella SG, Losey L, Hatsukami DK. A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiol Biomarkers Prev 2004;13(10):1617-1623.
68. Yang M, Koga M, Katoh T, Kawamoto T. A study for the proper application of urinary naphthols, new biomarkers for airborne polycyclic aromatic hydrocarbons. Arch Environ Contam Toxicol 1999;36(1):99-108.
69. Jansen EHJM, Schenk E, den Engrlsman G, van de Werken G. Use of biomarkers in exposure assessment of polycyclic aromatic hydrocarbons. Clin Chem 41:1905-1906.
70. Kim H, Kim YD, Lee H, Kawamoto T, Yang M, Katoh T. Assay of 2-naphthol in human urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;734(2):211-217.
71. Nan HM, Kim H, Lim HS, Choi JK, Kawamoto T, Kang JW, Lee CH, Kim YD, Kwon EH. Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations. Carcinogenesis 2001;22(5):787-793.
72. Wilson AS, Davis CD, Williams DP, Buckpitt AR, Pirmohamed M, Park BK Characterisation of the toxic metabolite(s) of naphthalene. Toxicology. 1996 Dec 18;114(3):233-242.
73. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5'-flanking region. J Biochem (Tokyo). 1994 Aug;116(2):321-326.
74. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 2002;181-182:447-452.
75. Park S, Kang H, Kang J, Park C, Yang M. Anayses of naphthalene metabolites using human CYP2E1 expressed HepG2 cell-microsome. Proceeding of The 55th annual meeting of the Korean society for Preventive Medicine 2003;353.
76. Simon P, Lafontaine M, Delsaut P, Morele Y, Nicot T. Trace determination of urinary 3-hydroxybenzo [a] pyrene by automated column-switching high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000;748(2):337-348.
77. Grimmer G, Jacob J, Dettbarn G, Naujack KW. Determination of urinary metabolites of polycyclic aromatic hydrocarbons (PAH) for the risk assessment of PAH-exposed workers. Int Arch Occup Environ Health 1997;69(4):231-239.
78. Wang JJ, Frazer DG, Stone S, Goldsmith T, Law B, Moseley A, Simpson J, Afshari A, Lewis DM. Urinary benzo[a]pyrene and its metabolites as molecular biomarkers of asphalt fume exposure characterized by microflow LC coupled to hybrid quadrupole time-of-flight mass spectrometry. Anal Chem 2003;75(21):5953-5960.
79. Emmons KM, Abrams DB, Marshall R, Marcus BH, Kane M, Novotny TE, Etzel RA. An evaluation of the relationship between self-report and biochemical measures of environmental tobacco smoke exposure. Prev Med 1994;23(1):35-39.
80. Heinrich J, Holscher B, Seiwert M, Carty CL, Merkel G, Schulz C. Nicotine and cotinine in adults' urine: The German Environmental Survey 1998. J Expo Anal Environ Epidemiol 2004;. Epub ahead of print
81. Collier AC. Pritsos CA Environmental tobacco smoke in the workplace: markers of exposure, polymorphic enzymes and implications for disease state. Chem Biol Interact 2003;146(3):211-224.
82. Davis R, Stiles M, deBethizy J, Reynolds J. Dietary nicotine: a source of unrinary cotinine. Food Chem Toxicol 1991;29:821-827.
83. Kim H, Lim Y, Lee S, Park S, Kim C, Hong C, Shin D. Relationship between environmental tobacco smoke and urinary cotinine levels in passive smokers at their residence. J Expo Anal Environ Epidemiol 2004;14(Suppl 1):S65-70.
84. Takeda N, Jitsunari F, Asakawa F, Suna S, Manabe Y, Fukunaga I, Gotoh A. Simultaneous determination of cotinine and creatinine by high performance liquid chromatography. Sangyo Igaku 1993;35(3):198-199.
85. Kintz P. Gas chromatographic analysis of nicotine and cotinine in hair. J Chromatogr 1992;580(1-2):347-353.
86. Kellogg MD, Behaderovic J, Bhalala O, Rifai N. Rapid and simple tandem mass spectrometry method for determination of serum cotinine concentration. Clin Chem 2004;50(11):2157-2159.
87. Binnie V, McHugh S, Macpherson L, Borland B, Moir K, Malik K. The validation of self-reported smoking status by analysing cotinine levels in stimulated and unstimulated saliva, serum and urine. Oral Dis 2004;10(5):287-293.
88. Ring Z, Lou XJ, Thorn CF, Benowitz NL. http://www.pharmgkb.org/search/ pathway/nicotine/nicotine.jsp
89. Yang M, Kunugita N, Kitagawa K, Kang SH, Coles B, Kadlubar FF, Katoh T, Matsuno K, Kawamoto T. Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. Cancer Epidemiol Biomarkers Prev 2001;10(6):589-593.
90. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 2004;22(5):419-425.
91. Scherer G, Richter E. Biomonitoring exposure to environmental tobacco smoke (ETS): a critical reappraisal. Hum Exp Toxicol 1997;16(8):449-459.
92. Anderson KE, Kliris J, Murphy L, Carmella SG, Han S, Link C, Bliss RL, Puumala S, Murphy SE, Hecht SS. Metabolites of a tobacco-specific lung carcinogen in nonsmoking casino patrons. Cancer Epidemiol Biomarkers Prev 2003;12(12):1544-1546.
93. Kushida H, Fujita K, Suzuki A, Yamada M, Endo T, Nohmi T, Kamataki T. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis 2000;21(6):1227-1232.
94. Divi RL, Beland FA, Fu PP, Von Tungeln LS, Schoket B, Camara JE, Ghei M, Rothman N, Sinha R, Poirier MC. Highly sensitive chemiluminescence immunoassay for benzo[a]pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring. Carcinogenesis 2002;23(12):2043-2049.
95. Pavanello S, Siwinska E, Mielzynska D, Clonfero E. GSTM1 null genotype as a risk factor for anti-BPDE-DNA adduct formation in mononuclear white blood cells of coke-oven workers. Mutat Res 2004;558(1-2):53-62.
96. Richter E, Rosler S, Scherer G, Gostomzyk JG, Grubl A, Kramer U, Behrendt H. Haemoglobin adducts from aromatic amines in children in relation to area of residence and exposure to environmental tobacco smoke. Int Arch Occup Environ Health 2001;74(6):421-428.
97. Hammond SK, Coghlin J, Gann PH, Paul M, Taghizadeh K, Skipper PL, Tannenbaum SR. Relationship between environmental tobacco smoke exposure and carcinogen-hemoglobin adduct levels in nonsmokers. J Natl Cancer Inst 1993;85(6):474-478.
98. Conney AH. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman Lecture. Cancer Res. 2003 Nov 1;63(21):7005-7031.
99. Asami S, Hirano T, Yamaguchi R, Tomioka Y, Itoh H, Kasai H. Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking. Cancer Res 1996;56(11):2546-2549.
100. Asami S, Manabe H, Miyake J, Tsurudome Y, Hirano T, Yamaguchi R, Itoh H, Kasai H. Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis 1997;18(9):1763-1766.
101. Kasai H. Chemistry-based studies on oxidative DNA damage: formation, repair, and mutagenesis. Free Radic Biol Med 2002;33(4):450-456.
102. Holmberg P, Stal M. Hamberg, Quantitative determination of 8-hydroxy-2′-deoxyguanosine in human urine by isotope dilution mass spectrometry: normal levels in hemochromatosis. Free Radic Biol Med 1999;26:129-135.
103. Ravanat JL, Duretz B, Guiller A, Duoki T, Cadet J. Isotope dilution high-performance liquid chromatography-electrospray tandem mass spectrometry assay for the measurement of 8-oxo-7,8-dihydro-2′-deoxyguanosine in biological samples. J Chromatogr B 1998;715:349-356.